Manager’s Amendment in FDA Safety and Landmark Advancements (FDASLA) Act Would Include and Allow Drug Importation

Earlier this month, Colorado BioScience Association (CBSA) engaged on the U.S. Food and Drug Administration’s (FDA) Safety and Landmark Advancements (FDASLA) Act. CBSA and our national partners support the critically important reauthorization of the FDA’s prescription drug, generic drug, biosimilar, and medical device user fee agreements. In a 13-9 vote, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee approved the FDASLA Act, which reauthorizes most of FDA’s user fee programs and other major provisions. It is important that this legislation ultimately passes for user fees reauthorization. The passed Senate HELP committee legislation included is a manager’s amendment that has a provision requiring the FDA to develop rules for importing drugs from Canada. The plan would allow states to build their own programs then apply for federal approval. It would also require the FDA to legalize personal importation.

According to a recent article in The Colorado Sun, “In…
Click here to view original post